High performance liquid chromatographic separation of clausenamide enantiomers with chiral –AGP stationary phase

<正>A method of high performance liquid chromatographic separation of clausenamide enantiomers with chiral-AGP(α_1-acid glycoprotein) stationary phases has been established.The absolute configurations of(-)clausenamide and(+)clausenamide are 3S, 4R,5R,6S and 3R,4S,5S,6R,respectively.The present method has been used to analyze the(-)clausenamide and(+)clausenamide and its analogues such as the major metabolite and synthetic derivatives of clausenamide.     

Study on the Synthesis of Metabolite of Clausenamide （CM1）

(-) Clausenamide (1) showed strong nootropic action, while its (+) antipode had no such an action. The content of CM1(2) in the metabolites of (-)1 is much higher than that of (+)11. For comparing the nootropic activity of enantiomers, (+) and (-) CM1 were synthesized. CM1 is the hydroxylated product of the N-methyl group of clausenamide. Oxidation of the C3-OH and C6-OH protected clausenamide to introduce the hydroxyl group into the methyl was tried but unsuccessful. Then de novo s…     

Studies on the chemical constituents of (Clausena Lansium) (Lour.) Skeels II: The isolation and structural elucidation of neoclausenamide and dehydrocycloclausenamide

Two novel lactams ( 2 and 8 ) with lowering effect on the elevated SGPT levels were isolated from leaves of Clausenamide lansium (Lour.) Skeels. Structural elucidations on the basis of their spectrometric data combined with chemical reactions, their interrelationship and relation to clausenamide were described.     

Determination of imidol hydrochloride in human plasma and urine by high-performance liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetic study

Imidol hydrochloride is a novel drug for the treatment of hepatitis B virus infection. A simple, special and sensitive solid‐phase extraction liquid chromatography–tandem mass spectrometry method for determination of imidol in human plasma and urine was developed for the first time and applied to a pharmacokinetic study. The chromatographic separation was achieved on a C₁₈ column (50 × 2.1 mm, 3.5 µm) using gradient elution with acetonitrile and water both containing 0.1% acetic acid at a flow rate of 0.25 mL/min. The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring mode via a positive eletrospray ionization source. The mass transition pairs of m/z 517.8 → 325 and m/z 298 → 174 were used to detect imidol and the (?)‐clausenamide (internal standard), respectively. The retention times of imidol and (?)‐clausenamide were 2.5 and 2.7 min, respectively. Linearity, accuracy, precision, recovery, matrix effect, dilution test and stability were evaluated during method validation over the range of 0.2–500 ng/mL in human plasma and 0.5–500 ng/mL in urine. The method was successfully applied to a clinical pharmacokinetic study of imidol in healthy volunteers following oral administration. Copyright © 2011 John Wiley & Sons, Ltd.     

Synthesis of Urinary Metabolites of Retinoic Acid

Urinary metabolites 5-methyl-5-[2-(2,6,6-trimethyl -3-oxo-1-cyclohexen-1-yl)-vinyl]-2-tetrahydrofuranone (1) and 5-[2-(6-hydroxymethyl-2, 6-dimethyl-3-oxo-1- cyclohexen-1-yl)vinyl]-5-methyl-2-tetrahydrofuranone (2) of retinoic acid have been synthesized from 4-[2,2,6-trimethyl-3-(tetrahydro-2 H -pyran-2-yl)oxy-1-cyclohexen-1-yl]-3-buten-2-one (4) and methyl 2-(3,3-ethylenedioxy-1-butenyl)-1, 3-dimethyl-4-oxo-2-cyclohexene-1-carboxylate (5) .     

间氯苯基锰卟啉-5-氟尿嘧啶配合物的合成及其对癌细胞的抑制活性

合成了4种新5-氟尿嘧啶-卟啉衍生物：5-[3-(2-(5-氟尿嘧啶-1-基)乙氧基)苯基]-10,15,20-三(3-氯苯基)卟啉(1a)、5-[3-(2-(5-氟尿嘧啶-1-基)乙氧基)苯基]- 10,15,20-三(3-氯苯基)锰卟啉(2a)、5-[3-(3-(5-氟尿嘧啶-1-基)丙氧基)苯基]-10,15,20-三(3-氯苯基)锰卟啉(2b)和5-[3-(4-(5-氟尿嘧啶-1-基)丁氧基)苯基]-10,15,20-三(3-氯苯基)锰卟啉(2c),通过UV-Vis、IR、MS及元素分析表征了它们的结构。 用噻唑蓝法（MTT法）测定了化合物2a、2b和2c对人胃癌细胞株BGC-823的抑制活性。 化合物2b的半数抑制浓度IC50为1.34 μmol/L,表明有一定的细胞毒作用。     

Syntheses of functionalized ferratricarbadecaboranyl complexes

The reactions of nitriles (RCN) with arachno-4,6-C(2)B(7)H(12)(-) provide a general route to functionalized tricarbadecaboranyl anions, 6-R-nido-5,6,9-C(3)B(7)H(9)(-), R = C(6)H(5) (2(-)), NC(CH(2))(4) (4(-)), (p-BrC(6)H(4))(Me(3)SiO)CH (6(-)), C(14)H(11) (8(-)), and H(3)BNMe(2)(CH(2))(2) (10(-)). Further reaction of these anions with (eta(5)-C(5)H(5))Fe(CO)(2)I yields the functionalized ferratricarbadecaboranyl complexes 1-(eta(5)-C(5)H(5))-2-C(6)H(5)-closo-1,2,3,4-FeC(3)B(7)H(9) (3), 1-(eta(5)-C(5)H(5))-2-NC(CH(2))(4)-closo-1,2,3,4-FeC(3)B(7)H(9) (5), 1-(eta(5)-C(5)H(5))-2-[(p-BrC(6)H(4))(Me(3)SiO)CH]-closo-1,2,3,4-FeC(3)B(7)H(9) (7), 1-(eta(5)-C(5)H(5))-2-C(14)H(11)-closo-1,2,3,4-FeC(3)B(7)H(9) (9), and 1-(eta(5)-C(5)H(5))-2-H(3)BNMe(2)(CH(2))(2)-closo-1,2,3,4-FeC(3)B(7)H(9) (11). Reaction of 11 with DABCO (triethylenediamine) resulted in removal of the BH(3) group coordinated to the nitrogen of the side chain, giving 1-(eta(5)-C(5)H(5))-2-NMe(2)(CH(2))(2)-closo-1,2,3,4-FeC(3)B(7)H(9) (12). Crystallographic studies of complexes 3, 5, 7, 9, and 11 confirmed that these complexes are ferrocene analogues in which a formal Fe(2+) ion is sandwiched between the cyclopentadienyl and tricarbadecaboranyl monoanionic ligands. The metals are eta(6)-coordinated to the puckered six-membered face of the tricarbadecaboranyl cage, with the exopolyhedral substituents bonded to the low-coordinate carbon adjacent to the iron.     

Identification and biological activity of microbial metabolites of xanthohumol

Microbial transformation of xanthohumol using the culture broth of Cunninghamella echinulata NRRL 3655 afforded (2S)-8-[4"-hydroxy-3"-methyl-(2"-Z)-butenyl]-4',7-dihydroxy-5-methoxyflavanone (5) and (2S)-8-[5"-hydroxy-3"-methyl-(2"-E)-butenyl]-4',7-dihydroxy-5-methoxyflavanone (6). Xanthohumol (1) and flavanone 6 as well as (E)-2"-(2"'-hydroxyisopropyl)-dihydrofurano[2",3":4',3']-2',4-dihydroxy-6'-methoxychalcone (2), (2S)-2"-(2"'-hydroxyisopropyl)-dihydrofurano[2",3":7,8]-4'-hydroxy-5-methoxyflavanone (3) obtained with Pichia membranifaciens showed antimalarial activity against Plasmodium falciparum.     

Synthesis of novel isoxazolyl bis-thiazolo[3,2-a]pyrimidines

A new synthetic strategy for the synthesis of novel 3-(3-(3-methyl-4-nitroisoxazol-5-yl)-2-phenyl-1-(5,7-diaryl-7H-thiazolo[3,2-a]pyrimidin-3-yl)propyl)-5,7-diaryl-7H-thiazolo[3,2-a] pyrimidines(7a-i) analogues is described.Reaction of 3-(2(3-methyl-4-nitroisoxazole-5-yl)-1-phenylethyl)pentane-2,4-dione(3) with two moles of thiourea in presence of iodine and CuO afforded 4-(1-(2-aminothiazol-4-yl)-3-(3-methyl-4-nitroisoxazol-5-yl)-2-aryl propyl-thiazol-2-amine(5).Compound 5 on reaction with two moles of chalcone(6) furnished novel 3-(3-(3-methyl-4-nitroisoxazol-5-yl)-2-phenyl-1-(5,7-diaryl-7H-thiazolo[3,2a]pyrimidin-3-yl)propyl)-5,7-diaryl-7H-thiazolo[3,2-a] pyrimidines(7a-i).     

新型苯并二氢呋喃合二酮酸类化合物的合成及其与整合酶分子对接研究

以阿魏酸甲酯为原料,通过氧化偶联构建2-芳基苯并二氢呋喃骨架,再经傅克酰基化和酯缩合反应依次制得(E)-3-［2-(4-羟基-3-甲氧基-5-乙酰基)苯基-3-甲氧羰基-7-甲氧基-2,3-二氢苯［b］并呋喃-5-基］丙烯酸甲酯（3）和(E)-3-［2-(4-羟基-3-甲氧基-5-甲氧羰基乙酰基)苯基-3-甲氧羰基-7-甲氧基-2,3二氢苯并［b］呋喃-5-基］丙烯酸甲酯（4）; 4经水解反应合成3-【2-羟基-3-甲氧基-5-｛5-［2-（甲氧基羰基）乙烯基］-7-甲氧基-3-甲氧羰基-2,3-二氢苯并［b］呋喃-2-｝基】苯基-3-氧丙酸（5）,化合物3~5未见文献报道,其结构经¹H NMR, ¹³C NMR和MS(ESI)表征。采用分子对接软件Autodock vina对化合物2~5与HIV-1整合酶核心部位高度同源的PFV IN（PDB: 3L2V）进行对接,计算结果显示该类化合物能与整合酶形成稳定的复合物,具有1,3-二酮基团的化合物3, 4和5能与整合酶中金属离子产生螯合作用,其中化合物5的结合作用最强。     

Synthesis, structure, and reactivity of palladacycles that contain a chiral rhenium fragment in the backbone: New cyclometalation and catalyst design strategies

The bromocyclopentadienyl complex [(eta5-C5H4Br)Re(CO)3] is converted to racemic [(eta5-C5H4Br)Re(NO)(PPh3)(CH2PPh2)] (1 b) similarly to a published sequence for cyclopentadienyl analogues. Treatment of enantiopure (S)-[(eta5-C5H5)Re(NO)(PPh3)(CH3)] with nBuLi and I2 gives (S)-[(eta5-C5H4I)Re(NO)(PPh3)(CH3)] ((S)-6 c; 84 %), which is converted (Ph3C+ PF6 -, PPh2H, tBuOK) to (S)-[(eta5-C5H4I)Re(NO)(PPh3)(CH2PPh2)] ((S)-1 c). Reactions of 1 b and (S)-1 c with Pd[P(tBu)3]2 yield [{(eta5-C5H4)Re(NO)(PPh3)(mu-CH2PPh2)Pd(mu-X)}2] (10; X = b, Br, rac/meso, 88 %; c, I, S,S, 22 %). Addition of PPh3 to 10 b gives [(eta5-C5H4)Re(NO)(PPh3)(mu-CH2PPh2)Pd(PPh3)(Br)] (11 b; 92 %). Reaction of (S)-[(eta5-C5H5)Re(NO)(PPh3)(CH2PPh2)] ((S)-2) and Pd(OAc)(2) (1.5 equiv; toluene, RT) affords the novel Pd3(OAc)4-based palladacycle (S,S)-[(eta5-C5H4)Re(NO)(PPh3)(mu-CH2PPh2)Pd(mu-OAc)2Pd(mu-OAc)2Pd(mu-PPh2CH2)(Ph3P)(ON)Re(eta5-C5H4)] ((S,S)-13; 71-90 %). Addition of LiCl and LiBr yields (S,S)-10 a,b (73 %), and Na(acac-F6) gives (S)-[(eta5-C5H4)Re(NO)(PPh3)(mu-CH2PPh2)Pd(acac-F6)] ((S)-16, 72 %). Reaction of (S,S)-10 b and pyridine affords (S)-[(eta5-C5H4)Re(NO)(PPh3)(mu-CH2PPh2)Pd(NC5H5)(Br)] ((S)-17 b, 72 %); other Lewis bases yield similar adducts. Reaction of (S)-2 and Pd(OAc)2 (0.5 equiv; benzene, 80 degrees C) gives the spiropalladacycle trans-(S,S)-[{(eta5-C5H4)Re(NO)(PPh3)(mu-CH2PPh2)}2Pd] (39 %). The crystal structures of (S)-6 c, 11 b, (S,S)- and (R,R)-132 C7H8, (S,S)-10 b, and (S)-17 b aid the preceding assignments. Both 10 b (racemic or S,S) and (S)-16 are excellent catalyst precursors for Suzuki and Heck couplings.     

Reaction of 3-acetonyl-5-cyano-1,2,4-thiadiazole with phenylhydrazine hydrochlorides: indolization and phenylpyrazolation

Treatment of 3-acetonyl-5-cyano-1,2,4-thiadiazole (1) with 4-methyl or 4-methoxyphenylhydrazine hydrochloride provided 5-cyano-3-(2,5-dimethylindol-3-yl)-1,2,4-thiadiazole (2) or 5-cyano-3-(5-methoxy-2-methylindol-3-yl)-1,2,4-thiadiazole (3) as the sole product, respectively. In contrast, treatment of 1 with phenylhydrazine hydrochloride resulted in the formation of 5-cyano-3-(2-methylindol-3-yl)-1,2,4-thiadiazole (4) and the unexpected 5-cyano-3-(3,5-dimethyl-1-phenylpyrazol-4-yl)-1,2,4-thiadiazole (5). In a similar manner, when 1 was treated with 4-chlorophenylhydrazine hydrochloride, indolization was suppressed by phenylpyrazolation giving rise to 5-cyano-3-(5-chloro-2-methylindol-3-yl)-1,2,4-thiadiazole (6) and 5-cyano-3-[1-(4-chlorophenyl)-3,5-dimethylpyrazol-4-yl]-1,2,4-thia diazole (7). The reaction mechanism is discussed. Compounds 4, 5 and 6 exhibited weak antimicrobial activity against Helicobacter pylori.     

Enantioselective self-assembly of bimetallic [Mn(II) (delta)-Cr(III)(C2O4)3]- and [Mn(II) (lambda)-Cr(III)(C2O4)3]- layered anionic networks templated by the optically active (Rp)- and (Sp)-[1-CH2N(n-C3H7)3-2-CH3-C5H3Fe-C5H5]+ ions

The ferrocenic ammonium (Rp)- and (Sp)-[1-CH2NR(3-)-2-CH3-C5H3Fe-C5H5] iodide salts with R=CH3, C2H5, n-C3H7, n-C4H9, were synthesized starting from the (Rp)- and (Sp)-[1-CH2N(CH3)2-2-CH3-C5H3Fe-C5H5] amines obtained in their optically active forms through asymmetric cyclopalladation of [C5H5Fe-C5H4CH2N(CH3)2]. 1H NMR studies of these planar chiral 1,2-disubstituted ferrocenic ammonium iodide salts in the presence of the (Delta)-(tris(tetrachlorobenzenediolato)phosphate(V) anion), [(Delta)-Trisphat] support the formation of specific diastereomeric ion pairs. Such intermolecular interactions can be related to the self-assembly of the two-dimensional optically active compounds [[(Sp)-1-CH2N(n-C3H7)3-2-CH3-C5H3Fe-C5H5][Mn (Delta)-Cr(C2O4)3]] and [[(Rp)-1-CH2N(n-C3H7)3-2-CH3-C5H3Fe-C5H5][Mn (Lambda)-Cr(C2O4)3]] starting from the resolved (Rp)- and (Sp)-[1-CH2N(n-C3H7)3-2-CH3-C5H3Fe-C5H5]+ ion associated to the racemic anionic building block rac-[Cr(C2O4)3]3- and Mn2+. Both enantiomeric forms of the networks behave as ferromagnets with a Curie temperature of 5.7 K.     

The C-disaccharide alpha-C(1-->3)-mannopyranoside of N-acetylgalactosamine is an inhibitor of glycohydrolases and of human alpha-1,3-fucosyltransferase VI. Its epimer alpha-(1-->3)-mannopyranoside of N-acetyltalosamine is not

The radical C-glycosidation of (-)-(1S,4R,5R, 6R)-6-endo-chloro-3-methylidene-5-exo-(phenylseleno)-7-ox abi cyclo[2. 2.1]heptan-2-one ((-)-4) with 2,3,4, 6-tetra-O-acetyl-alpha-D-mannopyranosyl bromide gave (+)-(1S,3R,4R, 5R,6R)-6-endo-chloro-5-exo-(phenylseleno)-3-endo-(1',3',4', 5'-tetra-O-acetyl-2', 6'-anhydro-7'-deoxy-D-glycero-D-manno-heptitol-7'-C-yl)-7-oxabi cyc lo[ 2.2.1]hept-2-one ((+)-5) that was converted into (+)-(1R,2S,5R, 6R)-5-acetamido-3-chloro-2-hydroxy-6-(1',3',4',5'-tetra-O-acetyl)-2', 6'-anhydro-7'-deoxy-D-glycero-D-manno-heptitol-7'-C-yl)cyclohex -3-en- 1-yl acetate ((+)-10) and into (+)-(1R,2S,5R, 6S)-5-bromo-3-chloro-2-hydroxy-6-(1',3',4',5'-tetra-O-acetyl-2', 6'-anhydro-7'-deoxy-D-glycero-D-manno-heptitol-7'-C-yl)cyclohex -3-en- 1-yl acetate ((+)-19). Ozonolysis of (+)-10 and further transformations provided 2-acetamido-2,3-dideoxy-3-C-(2', 6'-anhydro-7'-deoxy-D-glycero-D-manno-heptitol-7'-C-yl)-D-galac tos e (alpha-C(1-->3)-D-mannopyranoside of N-acetylgalactosamine (alpha-D-Manp-(1-->3)CH(2)-D-GalNAc): 1). Displacement of the bromide (+)-19 with NaN(3) in DMF provided the corresponding azide ((-)-20) following a S(N)2 mechanism. Ozonolysis of (-)-20 and further transformations led to 2-acetamido-2,3-dideoxy-3-C-(2', 6'-anhydro-7'-deoxy-D-glycero-D-manno-heptitol-7'-C-yl)-D-talose (alpha-C(1-->3)-D-mannopyranoside of N-acetyl D-talosamine (alpha-D-Manp-(1-->3)CH(2)-D-TalNAc): 2). The neutral C-disaccharide 1 inhibits several glycosidases (e.g., beta-galactosidase from jack bean with K(i) = 7.5 microM, alpha-L-fucosidase from human placenta with K(i) = 28 microM, beta-glucosidase from Caldocellum saccharolyticum with K(i) = 18 microM) and human alpha-1, 3-fucosyltransferase VI (Fuc-TVI) with K(i) = 120 microM whereas it 2-epimer 2 does not. Double reciprocal analysis showed that the inhibition of Fuc-TVI by 1 displays a mixed pattern with respect to both the donor sugar GDP-fucose and the acceptor LacNAc with K(i) of 123 and 128 microM, respectively.     

Synthesis and properties of 5-(1,2-dihaloethyl)-2′-deoxyuridines and related analogues

The regiospecific reaction of 5-vinyl-3′,5′-di-O-acetyl-2′-deoxyuridine ( 2 ) with HOX (X = Cl, Br, I) yielded the corresponding 5-(1-hydroxy-2-haloethyl)-3′,5′-di-O-acetyl-2′-deoxyuridines 3a-c . Alternatively, reaction of 2 with iodine monochloride in aqueous acetonitrile also afforded 5-(1-hydroxy-2-iodoethyl)-3′,5′-di-O-acetyl-2′-deoxyuridine ( 3c ). Treatment of 5-(1-hydroxy-2-chloroethyl)- ( 3a ) and 5-(1-hydroxy-2-bromoethyl)-3′,5′-di-O-acetyl-2′-deoxyuridine ( 3b ) with DAST (Et₂NSF₃) in methylene chloride at -40° gave the respective 5-(1-fluoro-2-chloroethyl)- ( 6a , 74%) and 5-(1-fluoro-2-bromoethyl)-3′,5′-di-O-acetyl-2′-deoxyuridine ( 6b , 65%). In contrast, 5-(1-fluoro-2-iodoethyl)-3′,5′-di-O-acetyl-2′-deoxyuridine ( 6e ) could not be isolated due to its facile reaction with methanol, ethanol or water to yield the corresponding 5-(1-methoxy-2-iodoethyl)- ( 6c ), 5-(1-ethoxy-2-iodoethyl)- ( 6d ) and 5-(1-hydroxy-2-iodoethyl)-3′,5′-di-O-acetyl-2′-deoxyuridine ( 3c ). Treatment of 5-(1-hydroxy-2-chloroethyl)- ( 3a ) and 5-(1-hydroxy-2-bromoethyl)-3′,5′-di-O-acetyl-2′-deoxyuridine ( 3b ) with thionyl chloride yielded the respective 5-(1,2-dichloroethyl)- ( 6f , 85%) and 5-(1-chloro-2-bromoethyl)-3′,5′-di-O-acetyl-2′-deoxyuridine ( 6g , 50%), whereas a similar reaction employing the 5-(1-hydroxy-2-iodoethyl)- compound 3c afforded 5-(1-methoxy-2-iodoethyl)-3′,5′-di-O-acetyl-2′-deoxyuridine ( 6c ), possibly via the unstable 5-(1-chloro-2-iodoethyl)-3′,5′-di-O-acetyl-2′-deoxyuridine intermediate 6h . The 5-(1-bromo-2-chloroethyl)- ( 6i ) and 5-(1,2-dibromoethyl)-3′,5′-di-O-acetyl-2′-deoxyuridine ( 6j ) could not be isolated due to their facile conversion to the corresponding 5-(1-ethoxy-2-chloroethyl)- ( 6k ) and 5-(1-ethoxy-2-bromoethyl)-3′,5′-di-O-acetyl-2′-deoxyuridine ( 61 ). Reaction of 5-(1-hydroxy-2-bromoethyl)-3′,5′-di-O-acetyl-2′-deoxyuridine ( 3b ) with methanolic ammonia, to remove the 3′,5′-di-O-acetyl groups, gave 2,3-dihydro-3-hydroxy-5-(2′-deoxy-β-D-ribofuranosyl)-furano[2,3-d]pyrimidine-6(5H)-one ( 8 ). In contrast, a similar reaction of 5-(1-fluoro-2-chloroethyl)-3′,5′-di-O-acetyl-2′-deoxyuridine ( 6a ) yielded (E)-5-(2-chlorovinyl)-2′-deoxyuridine ( 1b , 23%) and 5-(2′-deoxy-β-D-ribofuranosyl)furano[2,3-d]pyrimidin-6(5H)-one ( 9 , 13%). The mechanisms of the substitution and elimination reactions observed for these 5-(1,2-dihaloethyl)-3′,5′-di-O-acetyl-2′-deoxyuridines are described.     

Chiral Cyclopentane-Based Mimics of D-myo-Inositol 1,4,5-Trisphosphate from D-Glucose

Two routes from D-glucose to chiral, ring-contracted analogs of the second messenger D-myo-inositol 1,4,5-trisphosphate are described. Methyl alpha-D-glucopyranoside was converted by an improved procedure into methyl 4,6-O-(p-methoxybenzylidene)-alpha-D-glucopyranoside (6) and thence into methyl 2-O-benzyl-3,4-bis-O-(p-methoxybenzyl)-alpha-D-gluco-hexodialdopyranoside (1,5) (14) in four steps. In the first ring-contraction method 14 was converted into methyl 2-O-benzyl-6,7-dideoxy-3,4-bis-O-(p-methoxybenzyl)-alpha-D-gluco-hept-6-enopyranoside (1,5) (15), which on sequential treatment with Cp(2)Zr(n-Bu)(2) followed by BF(3).Et(2)O afforded a mixture of (1R,2S,3S,4R,5S)-3-(benzyloxy)-4-hydroxy-1,2-bis[(p-methoxybenzyl)oxy]-5-vinylcyclopentane (16) and its 4S,5R diastereoisomer 17. Removal of the p-methoxybenzyl groups of 16 and subsequent phosphorylation and deprotection afforded the first target compound, (1R,2R,3S,4R,5S)-3-hydroxy-1,2,4-tris(phosphonooxy)-5-vinylcyclopentane (3). In the second route, intermediate 14 was subjected to SmI(2)-mediated ring contraction to give (1R,2S,3S,4R,5S)-3-(benzyloxy)-4-hydroxy-5-(hydroxymethyl)-1,2-bis[(p-methoxybenzyl)oxy]cyclopentane (20). Benzylation of 20 provided (1R,2S,3S,4R,5S)-3-(benzyloxy)-6-[(benzyloxy)methyl]-4-hydroxy-1,2-bis[(p-methoxybenzyl)oxy]cyclopentane (22) and (1R,2S,3S,4R,5S)-3,4-bis(benzyloxy)-5-(hydroxymethyl)-1,2-bis[(p-methoxybenzyl)oxy]cyclopentane (21), which were elaborated to the target trisphosphates (1R,2R,3S,4R,5S)-3-hydroxy-5-(hydroxymethyl)-1,2,4-tris(phosphonooxy)cyclopentane (4) and (1R,2S,3R,4R,5S)-1,2-dihydroxy-3,4-bis(phosphonooxy)-5-[(phosphonooxy)methyl]cyclopentane (5), respectively. Both 3 and 4 mobilized intracellular Ca(2+), but 4 was only a few fold less potent than D-myo-inositol 1,4,5-trisphosphate, demonstrating that effective mimics can be designed that do not bear a six-membered ring.     

Rhenium tricarbonyl core complexes of thymidine and uridine derivatives

Thymidine and uridine were modified at the C2' and C5' ribose positions to form amine analogues of the nucleosides (1 and 4). Direct amination with NaBH(OAc)3 in DCE with the appropriate aldehydes yielded 1-{5-[(bis(pyridin-2-ylmethyl)amino)methyl]-4-hydroxytetrahydrofuran-2-yl}-5-methyl-1H-pyrimidine-2,4-dione (L1), 1-{5-[(bis(quinolin-2-ylmethyl)amino)methyl]-4-hydroxytetrahydrofuran-2-yl}-5-methyl-1H-pyrimidine-2,4-dione (L2), and 1-[3-(bis(pyridin-2-ylmethyl)amino)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-pyrimidine-2,4-dione (L5), while standard coupling procedures of 1 and 4 with 5-(bis(pyridin-2-ylmethyl)amino)pentanoic acid (2) and 5-(bis(quinolin-2-ylmethyl)amino)pentanoic acid (3) in the presence of HOBT-EDCI in DMF provided a second novel series of bifunctional chelators: 5-(bis(pyridin-2-ylmethyl)amino)pentanoic acid [(3-hydroxy-5-(5-methyl-4-oxo-3,4-dihydro-2H-pyrimidin-1-yl)tetrahydrofuran-2-yl)methyl] amide (L3), 5-(bis(quinolin-2-ylmethyl)amino)pentanoic acid [(3-hydroxy-5-(5-methyl-4-oxo-3,4-dihydro-2H-pyrimidin-1-yl)tetrahydrofuran-2-yl)methyl] amide (L4), 5-(bis(pyridin-2-ylmethyl)amino)pentanoic acid [2-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-3-yl] amide (L6), and 5-(bis(quinolin-2-ylmethyl)amino)pentanoic acid [2-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-3-yl] amide (L7). The rhenium tricarbonyl complexes of L1-L4, L6, and L7, [Re(CO)3(LX)]Br (X=1-4, 6, 7: compounds 5-10, respectively), have been prepared by reacting the appropriate ligand with [NEt4][Re(CO)3Br3] in methanol. The ligands and their rhenium complexes were obtained in good yields and characterized by common spectroscopic techniques including 1D and 2D NMR, HRMS, IR, cyclic voltammetry, UV, and luminescence spectroscopy and X-ray crystallography. The crystal structure of complex 6.0.5NaPF6 displays a facial geometry of the carbonyl ligands. The nitrogen donors of the tridentate ligand complete the distorted octahedral spheres of the complex. Crystal data: monoclinic, C2, a = 24.618(3) A, b = 11.4787(11) A, c = 15.5902(15) A, beta = 112.422(4) degrees , Z = 4, D(calc) = 1.562 g/cm3.     

Synthesis of some imidazole- and pyrazole- derived chelating agents

Procedures involving condensation of o-phenylenediamines with carboxylic acids, and reaction of bifunctional alkyl halides with bifunctional nucleophiles are described. Syntheses are reported of 2,6-bis-(2-benzimidazyl)-pyridine, 1,3-bis(2-benzimidazyl)-2-thiapropane, 1,7-bis(2-benzimidazyl)-2,6-dithiaheptane, 2-hydroxymethyl-5,6-dimethylbenzimidazole, 2-chloromethyl-5,6-dimethylbenzimidazole hydrochloride, 1,7-bis(5,6-dimethyl-2-benzimidazyl)-2,6-dithiaheptane, 3,6-bis(1-pyrazolyl)pyridazine, 2-(2-hydroxy-3-methyl–phenyl)benzimidazole, 2-(2-hydroxyphenyl)benzimidazole, 5-(2-hydroxphenyl)-3-methyl-1-phenylpyrazole, 3(5)-(2-hydroxyphenyl)-5(3)-methylpyrazole, 3(5)-(2-hydroxyphenyl)-5(3)-phenylpyrazole, and 1,3-bis((5-methylpyridyl)imino)isoindoline.     

Metal versus ligand alkylation in the reactivity of the (bis-iminopyridinato)Fe catalyst

The alkylation of the Brookhart-Gibson {2,6-[2,6-(i-Pr)2PhN=C(CH3)]2(C5H3N)} FeCl2 precatalyst with 2 equiv of LiCH2Si(CH3)3 led to the isolation of several catalytically very active products depending on the reaction conditions. The expected dialkylated species {2,6-[2,6-(i-Pr)2PhN=C(CH3)]2}(C5H3N)Fe(CH2SiMe3)2 (2) was indeed the major component of the reaction mixture. However, other species in which alkylation occurred at the pyridine ring ortho position, {2,6-[2,6-(i-Pr)2PhN=C(CH3)]2-2-CH2SiMe3}(C5H3N)Fe(CH2SiMe3) (1), and at the imine C atom, {2-[2,6-(i-Pr)2PhN=C(CH3)]-6-[2,6-(i-Pr)2PhNC(CH3)(CH2 SiMe3)](C5H3N)}Fe(CH2SiMe3) (3), have also been isolated and fully characterized. In addition, deprotonation of the methyl-imino functions and formation of a new divalent Fe catalyst {[2,6-[2,6-(i-Pr)2PhN-C=(CH2)]2(C5H3N)}Fe(mu-Cl)Li(THF)3 (4) also occurred depending on the reaction conditions. In turn, the formation of 4 might trigger the reductive coupling of two units through the methyl-carbon wings. This process resulted in the one-electron reduction of the metal center, affording a dinuclear Fe(I) alkyl catalyst {[{[2,6-(i-Pr)2C6H5]N=C(CH3)}(C5H3N){[2,6-(i-Pr)26H5]N=CCH2}Fe(CH2SiMe3)]}2 (5). Different from other metal derivatives, complex 5 could not be prepared from the monodeprotonated version of the ligand. Its reaction with a mixture of FeCl2 and RLi afforded instead [{2,6-[2,6-(i-Pr)2PhN-C=(CH2)]2(C5H3N)}FeCH2Si(CH3)3][Li(THF)4] (6) which is also catalytically active. All of these high-spin species have been shown to have high catalytic activity for olefin polymerization, producing polymers of two distinct natures, depending on the formal oxidation state of the metal center.     

三(三甲硅基)环戊二烯基三羰基钼负离子的反应性

三(三甲硅基)环戊二烯基三羰基钼负离子锂盐[{η^5-(Me~3Si)~3C~5H~2}Mo(CO)~3]^-Li^+(1), 分别与MeI、phCH~2Cl及ClCH~2COOC~2H~5反应生成相应的烃基化钼衍生物[{η^5-(Me~3Si)~3C~5H~2}Mo(CO)~3R,] (R=-CH~3, 2; -CH~2ph, 3;-CH~2COOC~2H~5, 4)。1与PCl~3反应除得到预期的钼氯化物[{η^5-(Me~3Si)~3C~5H~2}Mo(CO)~3Cl](5)外, 主要得到钼磷氯化物[{η^5-(Me~3Si)~3C~5H~2}Mo(CO)~3PCl~2] 6; 1与碘反应得到钼碘化物[{η^5-(Me~3Si)~3C~5H~2}Mo(CO)~3I] 7; 1与HOAc作用后分别和CCl~4、NBS室温反应, 仅分离到脱去一个Me~3Si的钼卤化物[{η^5-(Me~3Si)~2C~5H~2}Mo(CO)~3X], (X:Cl, 8; Br, 9)。